三菱商事、2018年度第1四半期決算公表

ENGLISH
|
JAPANESE
|
CONNECT WITH US:

2018年08月02日 14時00分

Source: Mitsubishi Corporation

三菱商事、2018年度第1四半期決算公表

東京, 2018年08月02日 - (JCN Newswire) - 三菱商事は８月２日（木）１４時に２０１８年度第１四半期決算公表を行いました。国際会計基準に基づく業績（連結決算）の主要項目は、以下の通りです。

当社の所有者に帰属する連結純利益
２０１８年度第１四半期決算　２，０４４億円
２０１７年度第１四半期決算　１,１７８億円

今回の決算では、最終的な損益を示す連結純利益は、２，０４４億円と、前年同期に比べ８６６億円、率にして７４%の増益となりました。
詳しくは、添付の２０１８年度第１四半期決算公表資料をご参照下さい。

本リリースの詳細は下記URLをご参照ください。
www.mitsubishicorp.com/jp/ja/pr/archive/2018/html/0000035324.html

概要：三菱商事株式会社

詳細は www.mitsubishicorp.com をご参照ください。

Source: Mitsubishi Corporation
セクター: エンジニアリング

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Latest Release

Mitsubishi Heavy Industries, Ltd.

World's First General Design Approval (GDA) for Developed Steel and Post-Weld Heat Treatment (PWHT) Exemption based on ECA for Low-pressure Liquefied CO2 Tank made of KF460 steel
Dec 05, 2025 18:17 JST

Hitachi, Ltd.

Hitachi at CES 2026: Building a Harmonized Society Through Technology
Dec 04, 2025 19:40 JST

Fujitsu and Scaleway partner to accelerate European sustainable transformation and data sovereignty with FUJITSU-MONAKA CPU-based AI inference
Dec 04, 2025 19:08 JST

NEC Corporation

NEC Orchestrating Future Fund Invests in PopID, Inc. to Accelerate Global Expansion of Biometric Payment Solutions and Launch a Strategic Collaboration
Dec 04, 2025 18:52 JST

Eisai

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
Dec 04, 2025 18:36 JST

HKTDC

The 26th Hong Kong Forum marks successful completion
Dec 03, 2025 22:44 JST

Eisai

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 03, 2025 18:19 JST

Mitsubishi Motors

Mitsubishi Motors Launches the All-New Destinator in Vietnam
Dec 03, 2025 18:00 JST

Anime Tokyo Station

Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Dec 03, 2025 11:30 JST

Eisai

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Dec 03, 2025 00:01 JST

NEC Corporation

NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI
Dec 02, 2025 23:43 JST

Fujitsu develops new technology to support human-robot collaboration
Dec 02, 2025 23:26 JST

Fujitsu establishes international consortium to tackle disinformation/misinformation and new AI risks
Dec 02, 2025 22:55 JST

Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Dec 01, 2025 23:04 JST

Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Dec 01, 2025 22:43 JST

Fujitsu launches 'Fujitsu Accelerator Program for SPORTS' to create new value through Sports x Technology
Dec 01, 2025 22:14 JST

Eisai

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST

NEC Corporation

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST

Mitsubishi Heavy Industries, Ltd.

MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST

Sharp Corporation

Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST

More Latest Release >>